Form 4: HealthEquity CFO Granted 27,283 Restricted Stock Units

HealthEquity's EVP & CFO, James M. Lucania, was granted 27,283 restricted stock units, vesting over several years.

Summary

• James M. Lucania, Executive Vice President & Chief Financial Officer of HealthEquity, Inc. (HQY), acquired 27,283 shares of common stock in the form of restricted stock units (RSUs).
• The transaction date for this acquisition was March 25, 2026.
• Each restricted stock unit represents a contingent right to receive one share of HealthEquity's common stock.
• The RSUs were acquired at a price of $0, which is typical for equity grants.
• Following this transaction, Mr. Lucania beneficially owns 111,849 shares directly.
• The shares will vest according to a schedule: 25% of the initial award vests on April 1, 2027, and then 6.25% vests on the first day of each calendar quarter for the twelve calendar quarters following April 1, 2027.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, as it represents a routine executive compensation action that aligns management's interests with long-term shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of restricted stock units aligns the financial interests of the EVP & CFO with those of the shareholders, incentivizing long-term performance.
• The use of a Rule 10b5-1 plan indicates a pre-planned and transparent approach to insider transactions.

Negatives

• The shares are restricted and do not provide immediate liquidity or full ownership until the vesting conditions are met.
• The value of the grant is contingent on the future stock price of HealthEquity, introducing market risk.

Risks

• The value of the restricted stock units is subject to the future market price fluctuations of HealthEquity's common stock.
• Forfeiture risk exists if the reporting person's employment terminates before the vesting schedule is complete.

Future Outlook

The future outlook for the reporting person includes the vesting of 27,283 restricted stock units over a period starting April 1, 2027, and continuing quarterly for three years, contingent on continued employment and the company's performance.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units is a standard practice in executive compensation across the healthcare technology sector. This method is widely used to attract, retain, and motivate key executives by aligning their long-term financial interests with the company's performance and shareholder value creation. It is consistent with compensation strategies observed at peer companies in the industry.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a common practice in the healthcare technology industry, aligning with global benchmarks for long-term incentive plans.
• Companies such as Teladoc Health (TDOC) and Cerner Corporation (now Oracle Health) frequently utilize RSU grants to incentivize their leadership, demonstrating a similar approach to executive retention and performance alignment.
• The multi-year vesting schedule is typical for RSU grants, designed to encourage sustained performance and long-term commitment from executives, comparable to structures seen in major tech and healthcare firms.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the EVP & CFO's long-term financial incentives with shareholder value creation, potentially leading to more focused management decisions aimed at increasing stock price.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, which can positively influence employee morale and retention.

Next Steps

• The restricted stock units will begin vesting on April 1, 2027, with subsequent vesting occurring quarterly thereafter.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU grant) and does not provide new information that would fundamentally alter the investment thesis for HealthEquity. While it aligns executive interests with shareholders, it is not a catalyst for a 'buy' or 'sell' recommendation on its own. Investors should 'hold' and consider broader company fundamentals and market conditions.

Keywords

HealthEquity, HQY, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Form 4, Corporate Governance, Rule 10b5-1